Chemours price target lowered to $27 from $34 at BMO Capital

BMO Capital analyst John McNulty lowered the firm’s price target on Chemours (CC) to $27 from $34 and keeps an Outperform rating on the shares after its Q4 earnings miss and guidance. The company’s Q1 will likely start slow though Chemours should still see solid earnings growth and free cash flow, even in a mediocre macro environment, with the help of tariffs and cost-cutting in Titanium Technologies segment along with corporate cost improvements, the analyst tells investors in a research note.